Bordeaux (France) – December 1, 2009 - Fluofarma announces publication in the journal “Analytical Chemistry” on its recombinant differential anchorage probes technology for high content screening.Fluofarma, a leading company in High Content Screening (HCS) technologies, which offers services and consultancy to the Pharmaceutical industry, announced today the publication in the international scientific journal “Analytical Chemistry”, of the original article "Recombinant differential anchorage probes that tower over the spatial dimension of intracellular signals for high content screening and analysis”.
....
About Fluofarma :
Fluofarma is a privately-held contract service provider which offers High Content Screening (HCS) services and technologies for target and drug discovery, predictive toxicity testing. The company was created in 2003 by a team of scientists with in-depth, expertise in oncology, neurobiology and chemistry. Since its inception, Fluofarma has developed innovative technologies designed for automated flow cytometry, confocal microscopy and laser scanning cytometry to improve the level of understanding of compounds and their effects, from the earliest stage of the discovery process onwards.
Fluofarma’ services include:
- Development & miniaturization of cell-based assays,
- Functional screening for target and drug discovery,
- Compound profiling and mechanism of action studies,
- Predictive toxicity testing at a large scale.
The company is headquartered in Bordeaux, France, and now works with over 30 major pharmaceutical and biotechnology companies worldwide... Fluofarma's Press Release -
